Intravitreal Methotrexate Gets Orphan Drug Status for Retinitis Pigmentosa
The FDA has granted Orphan Drug designation to ADX-2191 (methotrexate for intravitreal injection) for the treatment of retinitis pigmentosa.
Home
Cytisine vs Varenicline for Smoking Cessation: Results From a Noninferiority Trial
The researchers wanted to know if standard cytisine treatment for 25 days was at least as effective for smoking cessation as standard varenicline treatment for 84 days.
Can the Genetic Overlap of ADHD and Autism Guide Better Treatment?
Study researchers investigated the genetic overlap between ADHD and autism to determine if shared gene variants may provide insight into treatment targets.
Cytomegalovirus Seropositivity May Affect Epigenetic Aging in Healthy Older Adults
Investigators conducted a study to determine whether cytomegalovirus affects epigenetic age and immune dysregulation in healthy older adults who are asymptomatic.
A Definition of Textbook Outcome in Liver Surgery
Investigators attempted to reach international agreement on the definition of textbook outcome in liver surgery and to assess occurrence of this outcome following liver resection.
Frailty Linked to Neurocognitive Decline in Young Adult Survivors of Childhood Cancer
Frail survivors of childhood cancer experienced greater neurocognitive decline.
FDA Grants Fast Track Status to mRNA Respiratory Syncytial Virus Vaccine Candidate
mRNA-1345 is a vaccine candidate against RSV that utilizes the same lipid nanoparticle as Moderna’s authorized COVID-19 vaccine.
Aviptadil Gets Orphan Drug Status for Sarcoidosis
RLF-100 (aviptadil) is an inhaled, synthetic formulation of vasoactive intestinal peptide (VIP) for the treatment of sarcoidosis.
Study Shows Loneliness Tied to Use of High-Risk Medications
The study authors utilized the National Social Life, Health, and Aging Project leave-behind questionnaire to obtain data on a total of 6017 adults over 65 years of age.
Saphnelo Approved for Systemic Lupus Erythematosus
The Food and Drug Administration (FDA) has approved Saphnelo (anifrolumab-fnia) for the treatment of adults with moderate to severe systemic lupus erythematosus who are receiving standard therapy. Type I interferons (IFNs) play a role in the pathogenesis of systemic lupus erythematosus (SLE). Anifrolumab-fnia, a human immunoglobulin G1 kappa monoclonal antibody, binds to subunit 1 of…
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in News
Loading... 
Loading...